PRESERVE Preventing rejection and ensuring survival of grafts
- Coordinator
- Institut Pasteur, France
- Runs
- 1 February 2025 to 31 July 2026
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101188820
What the project is doing
In the project's own words, from its summary on CORDIS.
The success of organ transplantation depends on the lifelong use of immunosuppressive drugs to prevent rejection of the donor cells by the recipients immune system. These immunosuppressive drugs have several limitations, most notably major side effects, namely opportunistic infections and cancers. We have recently shown that the bacterial pathogen Listeria monocytogenes (Lm) induces the resistance of infected cells to T-cell mediated killing.
This project aims to protect grafted cells from T cell-mediated killing and thereby mitigate organ rejection. This will lay the groundwork for patent filing and the establishment of a robust business model to ensure further development and clinical translation. This innovative approach is expected to reduce the need for immunosuppressive therapy in transplant recipients, thereby improving outcomes and quality of life for the 130,000 patients who receive transplants worldwide each year.
This proof-of-concept project is based on our recently published study (Maudet et al, Nature 2022) supported by the ERC Invadis grant.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut Pasteur | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI